Diakonos Oncology Appoints Biotech Veteran Anthony Baldor as Chief Financial Officer
Diakonos Oncology Corp. (“Diakonos”), a clinical stage immuno-oncology company, announced today that Anthony Baldor has been appointed Chief Financial Officer.
- Diakonos Oncology Corp. (“Diakonos”), a clinical stage immuno-oncology company, announced today that Anthony Baldor has been appointed Chief Financial Officer.
- Mr. Baldor brings 20 years of financial management experience in the biotech industry including fundraising, business development, and corporate strategy.
- Mr. Baldor comes to Diakonos from 4D Molecular Therapeutics where he played critical leadership roles in the Series C, IPO and partnership activities as Vice President of Corporate Strategy and Development.
- “Anthony Baldor is a critical and timely addition to the Diakonos management team,” said Diakonos Chief Executive Officer Mike Wicks.